Medtronic plc. Ordinary Shares (NYSE:MDT) Signs Up Its First Patient In The IN.PACT(TM) AV Access Drug-Coated Balloon (DCB) Study

Medtronic plc. Ordinary Shares (NYSE:MDT) has confirmed having registered its first patient for the IN.PACT(TM) AV Access Drug-Coated Balloon (DCB) study. This will primarily involve patients with end-stage renal disease (ESRD) and will be evaluating the safety and usefulness of IN.PACT AV Access DCB.

Story continues below

The study will be carried out across 30 sites in the U.S., Japan, and New Zealand and could extend for up to two years. It is designed in a way that it will avail superior clinical alternatives for patients with restricted AV access.

Treatment options for patients with obstructed AV access are limited

Records have it that more than 2.5 million patients are suffering from end-stage renal disease thus they need to undertake the dialysis procedure. However, more often than not, the patients are limited by thickening of the vessel walls. Hence they cannot use a dialysis access site. It is at this point that The AV access sites comes in and will be used to provide hemodialysis to them.

The principal investigator at Richmond Vascular Center in Richmond, Jeffrey Hull notes, “Maintaining access patency is critical to delivering dialysis treatment, and for salvaging failing AV fistulas. Durable treatment options in these patients are limited.”

Meanwhile, there is a lot of optimism from Medtronic management of having the study provide significant data that will help in reducing the requirement for repeated interventions in AV access sites for patients on dialysis.

Medtronic’s aim is to enhance care in patients with ESRD

According to the national principal investigator in the U.S. Robert A. Lookstein, the primary purpose of this study is to address the clinical need of patients through innovative means. In the long run, it aims to enroll 330 patients. While at this it is worth taking note of the expansion of the market for end-stage renal disease therapy.

On the other hand, Medtronic has demonstrated its commitment and focus on strengthening its foothold in the delivery of improved health care for patients. It is one of the celebrated medical technology companies that help in restoring health and extending life for millions of people. In the meantime, Medtronic’s stock was trading at $85.58 witnessing an increase of $0.88 or 1.04%.

An ad to help with our costs